<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406819</url>
  </required_header>
  <id_info>
    <org_study_id>KS-2017-176</org_study_id>
    <nct_id>NCT03406819</nct_id>
  </id_info>
  <brief_title>Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI</brief_title>
  <acronym>NOSLOWFLOW-Ⅰ</acronym>
  <official_title>Prevention of Coronary Slow Flow or No-Reflow During Primary Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anyang Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huaihe Hospital of Henan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yellow River Sanmenxia hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Peoples' Hospital of Jiaozuo City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jincheng People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The second people's Hospital of Jiyuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaifeng Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lushan People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Pingdingshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenma Medical Group General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puyang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puyang Oil Field General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Shangqiu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yanshi People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Xinmi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xinxiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People’s Hospital of Zhengzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou First People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Cardiovascular Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 99th Central Hospital of the People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhoukou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Zhumadian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhumadian Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary percutaneous coronary intervention (PPCI) is the gold standard of treatment of ST
      segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following
      PPCI in STEMI patients has been a serious and common complication that closely related to the
      incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No
      reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not
      satisfactory. This prospective randomized controlled study aimed to compare favorable effects
      of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon
      during PPCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow grade after stent implantation</measure>
    <time_frame>1 minute after stent implantation</time_frame>
    <description>Grade 0, no myocardial blush or contrast density; grade 1, minimal myocardial blush or contrast density; grade 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery; grade 3, normal myocardial blush or contrast density comparable with that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary artery flow using TIMI flow grade after balloon dilatation</measure>
    <time_frame>1 minute after balloon dilatation</time_frame>
    <description>Grade 0, no myocardial blush or contrast density; grade 1, minimal myocardial blush or contrast density; grade 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery; grade 3, normal myocardial blush or contrast density comparable with that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary TIMI frame count after stent implantation</measure>
    <time_frame>1 minute after stent implantation</time_frame>
    <description>A continuous measurement assessing flow in the epicardial arteries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary TIMI frame count after balloon dilatation</measure>
    <time_frame>1 minute after balloon dilatation</time_frame>
    <description>A continuous measurement assessing flow in the epicardial arteries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow flow / no-reflow phenomenon after stent implantation</measure>
    <time_frame>1 minute after stent implantation</time_frame>
    <description>Slow flow phenomenon means delayed progression or lack of contrast medium through the coronary tree.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow flow / no-reflow phenomenon after balloon dilatation</measure>
    <time_frame>1 minute after balloon dilatation</time_frame>
    <description>Slow flow phenomenon means delayed progression or lack of contrast medium through the coronary tree.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG ST-segment fall more than 50%</measure>
    <time_frame>in 2 hours post-PCI</time_frame>
    <description>The extent of ST segment elevation was reduced by more than 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>at 1 day post-PCI, at follow up of 1, 3, 6,12 months post-PCI</time_frame>
    <description>Death, Cardiac death, Rehospitalization (Heart failure) , Non-fatal myocardial infarction, Target vessel myocardial infarction, Target lesion revascularization, Target vessel revascularization, Ischemic-driven revascularization, Stent thrombosis, Bleeding, Cerebrovascular events, etc.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>ST Segment Elevation Myocardial Infarction</condition>
  <condition>Primary Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Nitroprusside group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirofiban group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroprusside Sodium</intervention_name>
    <description>Intracoronary infusion 50~100μg each time (repeated)</description>
    <arm_group_label>Nitroprusside group</arm_group_label>
    <other_name>Experimental-1 group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban Hydrochloride</intervention_name>
    <description>Intracoronary infusion 10μg/kg for single time</description>
    <arm_group_label>Tirofiban group</arm_group_label>
    <other_name>Experimental-2 group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparinized saline</intervention_name>
    <description>Intracoronary infusion 2ml for single time</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic symptoms &lt; 12h, or evidence of ongoing ischemia 12h after symptom onset

          -  Continued ischemic chest pain &gt; 30min

          -  ST-segment elevation ≥ 0.1 millivolt in 2 or more contiguous leads on the 12-lead ECG
             or new left bundle branch block (LBBB)

          -  Detection of a rise of cardiac biomarker values with at least one value above the 99th
             percentile upper reference limit (URL)

          -  Primary coronary artery angiography was planned.

        Exclusion Criteria:

          -  Emergency thrombolytic therapy was performed before primary coronary artery
             angiography

          -  Cardiogenic shock with no response to hypervolemic treatment or vasopressor

          -  Severe cardiomyopathy or valvular disease requiring intervention

          -  Coronary ectasia

          -  Severe heart failure

          -  Contraindication or allergy to antiplatelet drugs

          -  Contraindication or allergy to experimental drugs

          -  Unable to receive at least 1 year of dual antiplatelet therapy

          -  Active bleeding or extreme-risk for major bleeding

          -  Severe liver or renal failure

          -  Life expectancy &lt; 1 year

          -  Unable or unwilling to provide informed consent

          -  Women of child bearing potential

          -  Under 18 years of age

          -  Hemoglobin &lt; 90g/L

          -  Platelet count &lt; 100×10^9/L

          -  Can not cooperate (with mental disorders or cognitive disorders)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunguang Qiu, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunguang Qiu, Phd</last_name>
    <phone>+86-13803898806</phone>
    <email>qcg123@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Pan, MD</last_name>
    <phone>+86-15003851743</phone>
    <email>huzhoupanliang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anyang District Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The 99th Central Hospital of the People's Liberation Army</name>
      <address>
        <city>Jiaozuo</city>
        <state>Henan</state>
        <zip>454000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Jiaozuo</name>
      <address>
        <city>Jiaozuo</city>
        <state>Henan</state>
        <zip>454002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The second people's Hospital of Jiyuan</name>
      <address>
        <city>Jiyuan</city>
        <state>Henan</state>
        <zip>454000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huaihe Hospital of Henan University</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <zip>475000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaifeng Central Hospital</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <zip>475000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lushan People's Hospital</name>
      <address>
        <city>Lushan</city>
        <state>Henan</state>
        <zip>467300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanyang City Center Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pingmei Shenma Medical Group General Hospital</name>
      <address>
        <city>Pingdingshan</city>
        <state>Henan</state>
        <zip>467000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Pingdingshan</name>
      <address>
        <city>Pingdingshan</city>
        <state>Henan</state>
        <zip>467000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puyang Oilfield General Hospital</name>
      <address>
        <city>Puyang</city>
        <state>Henan</state>
        <zip>457000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puyang People's Hospital</name>
      <address>
        <city>Puyang</city>
        <state>Henan</state>
        <zip>457099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yellow River Sanmenxia hospital</name>
      <address>
        <city>Sanmenxia</city>
        <state>Henan</state>
        <zip>472000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Shangqiu</name>
      <address>
        <city>Shangqiu</city>
        <state>Henan</state>
        <zip>476000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinyang Central Hospital</name>
      <address>
        <city>Xinyang</city>
        <state>Henan</state>
        <zip>464000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yanshi People's Hospital</name>
      <address>
        <city>Yanshi</city>
        <state>Henan</state>
        <zip>471900</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhengzhou First People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Cardiovascular Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Central Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunguang Qiu, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Xinmi</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>452370</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhoukou Central Hospital</name>
      <address>
        <city>Zhoukou</city>
        <state>Henan</state>
        <zip>466000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Zhumadian</name>
      <address>
        <city>Zhumadian</city>
        <state>Henan</state>
        <zip>463000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhumadian Central Hospital</name>
      <address>
        <city>Zhumadian</city>
        <state>Henan</state>
        <zip>463000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jincheng People's Hospital</name>
      <address>
        <city>Jincheng</city>
        <state>Shanxi</state>
        <zip>048026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Chunguang Qiu</investigator_full_name>
    <investigator_title>Director of the Department of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Slow flow</keyword>
  <keyword>No reflow</keyword>
  <keyword>Nitroprusside</keyword>
  <keyword>Tirofiban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

